Trial Profile
Phase IB Trial of LDE225 and Weekly Paclitaxel in Recurrent Platinum Resistant Ovarian Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Sonidegib (Primary) ; Paclitaxel
- Indications Ovarian cancer
- Focus Adverse reactions
- 01 Nov 2017 Status changed from active, no longer recruiting to completed.
- 18 Sep 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Dec 2017.
- 06 Feb 2017 Status changed from recruiting to active, no longer recruiting.